Has multivessel angioplasty displaced surgical revascularization?

Area of Science:

• Cardiology
• Interventional Cardiology
• Vascular Surgery

Background:

• Percutaneous transluminal coronary angioplasty (PTCA) is established as a safe and effective treatment for single-vessel coronary artery disease (CAD).
• Technological advancements in balloon, guidewire, and guide catheter technology have enabled the expansion of PTCA to treat multivessel CAD.
• Established guidelines aid in selecting appropriate cases for PTCA, though its role relative to surgery is still evolving.

Purpose of the Study:

• To review the current status and evolving role of PTCA in managing coronary artery disease, particularly multivessel CAD.
• To compare the efficacy and indications of PTCA versus coronary artery bypass grafting (CABG) for different CAD presentations.
• To discuss the impact of technological advancements and ongoing research on treatment strategies.

Main Methods:

• Review of historical data and clinical outcomes of PTCA for single and multivessel CAD.
• Analysis of technological developments facilitating PTCA procedures.
• Discussion of current guidelines and the necessity of surgical standby for PTCA.
• Consideration of ongoing randomized trials comparing PTCA and CABG.

Main Results:

• PTCA demonstrates satisfactory success rates and acceptable complication rates for multivessel CAD, supported by technological progress.
• Surgical intervention remains the preferred treatment for left main coronary artery disease and may be necessary for complex multivessel disease.
• Emergency surgical backup is essential for managing potential complications during PTCA procedures.
• The long-term efficacy, cost-effectiveness, and event limitation of PTCA versus CABG are under investigation in ongoing trials.

Conclusions:

• PTCA is a valuable therapeutic option for CAD, increasingly applied to multivessel disease due to technological advancements.
• Despite PTCA's success, coronary artery bypass grafting (CABG) retains its primary role in specific complex cases, such as left main disease.
• Further evidence from randomized trials is required to definitively establish the optimal revascularization strategy for multivessel CAD regarding long-term survival and outcomes.